Autolus Therapeutics Announces Publication in Molecular Therapy Nucleic Acids

April 26, 2023

https://www.globenewswire.com/news-release/2023/04/26/2655612/0/en/Autolus-Therapeutics-Announces-Publication-in-Molecular-Therapy-Nucleic-Acids.html

LONDON, April 26, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the publication of a paper in Molecular Therapy Nucleic Acids1, titled ‘Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T-cell efficacy.’

Read more at globenewswire.com

Related news for (AUTL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.